Cargando…
Antiviral drugs against SARS-CoV-2
The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral replication occurs around the symptom’s onset, and it prolongs for 5 to 7 d...
Autores principales: | Aiello, Tommaso Francesco, García-Vidal, Carolina, Soriano, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717461/ https://www.ncbi.nlm.nih.gov/pubmed/36285850 http://dx.doi.org/10.37201/req/s03.03.2022 |
Ejemplares similares
-
Neutralizing antibodies for SARS-CoV-2 infection
por: Berenguer, Juan
Publicado: (2022) -
Vulnerability to SARS-CoV-2 infection and disease: ripping the curl after the storm
por: Barreiro, Pablo, et al.
Publicado: (2022) -
Thrombose und COVID-19
por: Tzaneva, Stanislava
Publicado: (2021) -
Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection
por: Chua, Kyra Y.L., et al.
Publicado: (2020) -
In vitro evaluation of the virucidal activity of disodium citrate perhydrate (2SCP) disinfectant against SARS-CoV-2
por: Dessilly, Géraldine, et al.
Publicado: (2022)